...
CAILARGE

Caris Life Sciences, Inc.

HealthcareBiotechnology
$19.86
$0.01(+5.10%)
52W$17.15
$42.50
FinancialsValuationvs VCYT
Updated Mar 5, 12:00 AM
RSI38
RS Rating13/99
Beta1.09
Volatility58%
F-Score5/9
Mkt Cap$33.2B
DOWNTREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

DOWNTREND

Caris Life Sciences, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 13), showing significant lag compared to the market leaders. Earnings contraction of 141% provides fundamental context to the price action. Investors should exercise caution due to high volatility (58% annualized), which requires wider risk management.

Relative Strength
13
out of 99
Lagging
Trend Score
0/4
Minervini Criteria
DOWNTREND
Risk (Beta)
1.09
vs S&P 500
MARKET
52W Position
11%
from 52W low
Near Low
Trend & Momentum Analysis

Trend Template (Minervini)

DOWNTREND0/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$24.12
50 SMA > 100 SMA$25.96
100 SMA > 150 SMA$28.41
150 SMA > 200 SMA$—

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$20.40-2.65%BELOW
50 SMA$24.12-17.68%BELOW
100 SMA$25.96-23.51%BELOW
150 SMA$28.41-30.10%BELOW
200 SMA$——

Price Performance

1D+5.1%
1W+3.2%
1M-6.5%
3M-31.2%
6M-43.0%
YTD-26.4%
1Y-29.1%
3Y-10.8%
52-Week Trading Range11% from low
$19.86
52W Low$17.15
52W High$42.50

Technical Indicators

RSI (14)BEARISH
38.4
305070
VCP Score—
—/10
Base depth: —%

Risk Profile

Beta
1.09
52W Vol
58%
ATR
$1.26
Max DD (1Y)
-55%

Volume Analysis

Today
2.07M
50D Avg
2.29M
Vol Ratio
0.90x
Liquidity
MODERATE

Earnings Momentum

Q1'25-151%
$-0.40
Q2'25-192%
$-1.87
Q3'25-96%
$0.08
Q4'25-135%
$-1.03
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+13.56%
5 Years:+14.28%
3 Years:+46.46%
TTM:+144.85%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:-140.63%

Stock Price CAGR

10 Years:-3.38%
5 Years:-6.64%
3 Years:-10.82%
1 Year:-29.07%

Return on Equity

10Y Avg:-7.3%
5Y Avg:-44.6%
3Y Avg:-93.2%
Last Year:-93.2%

Key Metrics

Market Cap$33.2B
Gross Margin—
Net Margin-66.2%
Piotroski F-Score5/9

More CAI Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

CAI vs VCYTVCYTADPTNAUTCDIO

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 13 meansCAI outperformed 13% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.09 means 9% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of N/A/10 with N/A status.

Frequently Asked Questions

Is CAI in an uptrend right now?

CAI has a trend score of 0/4 based on Minervini's Stage Analysis. Currently showing broken structure - 0 of 4 trend criteria are met.

Is CAI overbought or oversold?

CAI's RSI (14) is 38. The stock is in neutral territory, neither overbought nor oversold.

Is CAI outperforming the market?

CAI has a Relative Strength (RS) Rating of 13 out of 99. CAI is currently lagging the broader market.

Where is CAI in its 52-week range?

CAI is trading at $19.86, which is 47% of its 52-week high ($42.50) and 11% above its 52-week low ($17.15).

How volatile is CAI?

CAI has a Beta of 1.09 and 52-week volatility of 58%. It's more volatile than the S&P 500 - expect bigger swings.